PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21130040-2	2011	At 0.03 muM to 1 muM, lenalidomide enhanced generation of IL-2 and IFN-gamma by T cell receptor-stimulated T cells of young subjects up to respective maximum increases of 17-fold and three-fold, but at 0.3 muM and 1 muM suppressed IL-17 generation.	Lenalidomide	22-34	latexin	Homo sapiens	8-11	
22623160-3	2012	The combination of Enzastaurin and Lenalidomide, at doses as low as 1 muM, showed strong synergism against indolent lymphomas by reducing cell growth, producing an increase in G0-G1 phase followed by significant decrease in S phase, increasing apoptosis, and inhibiting PI3K/AKT, PKC and MAPK/ERK pathways.	Lenalidomide	35-47	latexin	Homo sapiens	70-73	
22109882-8	2012	Whereas lenalidomide alone had no effect on cell growth, a 50% inhibition of cell growth by 1,25-D3 was achieved with additional 1 muM lenalidomide in resistant cells.	Lenalidomide	135-147	latexin	Homo sapiens	131-134	
21130040-2	2011	At 0.03 muM to 1 muM, lenalidomide enhanced generation of IL-2 and IFN-gamma by T cell receptor-stimulated T cells of young subjects up to respective maximum increases of 17-fold and three-fold, but at 0.3 muM and 1 muM suppressed IL-17 generation.	Lenalidomide	22-34	latexin	Homo sapiens	17-20	
26231201-6	2015	Treatment of human myeloma cell lines such as MM1.S, OPM2, and U266 with thalidomide (100 muM) and its structural analog lenalidomide (10 muM) results in stabilization of CRBN and elevation of CRBN protein levels.	Lenalidomide	121-133	latexin	Homo sapiens	138-141	
21130040-2	2011	At 0.03 muM to 1 muM, lenalidomide enhanced generation of IL-2 and IFN-gamma by T cell receptor-stimulated T cells of young subjects up to respective maximum increases of 17-fold and three-fold, but at 0.3 muM and 1 muM suppressed IL-17 generation.	Lenalidomide	22-34	latexin	Homo sapiens	17-20	
21130040-2	2011	At 0.03 muM to 1 muM, lenalidomide enhanced generation of IL-2 and IFN-gamma by T cell receptor-stimulated T cells of young subjects up to respective maximum increases of 17-fold and three-fold, but at 0.3 muM and 1 muM suppressed IL-17 generation.	Lenalidomide	22-34	latexin	Homo sapiens	17-20